Clarity Pharmaceuticals' 64Cu-SAR-bisPSMA Outperforms Standard in Prostate Cancer Detection
Event summary
- Clarity Pharmaceuticals presented Co-PSMA trial data at EAU Annual Congress 2026, showing 64Cu-SAR-bisPSMA identified 2.6x more lesions than 68Ga-PSMA-11 in prostate cancer recurrence detection.
- The study's primary endpoint was met with a mean per-patient lesion difference of 0.78 (p < 0.0001) between 64Cu-SAR-bisPSMA and 68Ga-PSMA-11.
- 64Cu-SAR-bisPSMA demonstrated a 71% true positive rate vs. 29% for 68Ga-PSMA-11, leading to management changes in 44% of trial participants.
- Data accepted for publication in European Urology (impact factor 25.2) and intended for FDA submission alongside COBRA and AMPLIFY trial results.
The big picture
Clarity Pharmaceuticals' positive Co-PSMA trial results position its 64Cu-SAR-bisPSMA as a potential next-generation diagnostic tool for prostate cancer recurrence detection. The data suggests significant advantages over current standard-of-care imaging, which could reshape treatment decision-making for patients with biochemical recurrence. The upcoming FDA submission represents a critical inflection point for the company's commercial prospects in the growing radiopharmaceutical market.
What we're watching
- Regulatory Pathway
- Whether the combined Co-PSMA, COBRA, and AMPLIFY data will constitute a compelling package for FDA approval of 64Cu-SAR-bisPSMA.
- Commercialization Timing
- The pace at which Clarity can bring 64Cu-SAR-bisPSMA to market following potential approval, given its Fast Track Designations.
- Competitive Positioning
- How this diagnostic performance advantage may position Clarity against existing PSMA PET agents in the prostate cancer recurrence detection market.
Related topics